Although infiltration of IL-17-secreting Th17 cells promotes resistance to the combination therapy, neutralization of IL-17 abrogates resistance, produces sustained activated CD8+ T-cell levels and lung tumor reduction, validating a promising triple combinatorial treatment strategy to overcome single-agent or combination therapy drug resistance in KRAS driven lung cancers (Fig. 7c). This evidence concerns the gene KRAS and lung cancer.